<div class="embed-responsive embed-responsive-16by9"><iframe width="640" height="360" style="max-width: 100%;max-height: 100%; border:none;" src="https://oncologytube.com/videoEmbed/28749/what-is-keynote-240-outcome-in-hcc?channelName=obr&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit=" frameborder="0" allowfullscreen="allowfullscreen" allow="autoplay" scrolling="no">iFrame is not supported!</iframe></div>

What is KEYNOTE 240 Outcome in HCC

Name: What is KEYNOTE 240 Outcome in HCC
Uploaded: 2019-06-28T06:36:17
Duration: 3 min 8 s
Description: Daneng Li, MD, Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research, Liver Program Disease Team Lead, City of Hope, explains the outcomes from KEYNOTe 240 trial comparing pembrolizumab versus placebo in 1st line hepatocellular carcinoma (HCC) patients.

00:03:08

Don

3 years 130 Views

Share Add to Report 0 0

Embed (Iframe):

<div class="embed-responsive embed-responsive-16by9"><iframe width="640" height="360" style="max-width: 100%;max-height: 100%; border:none;" src="https://oncologytube.com/videoEmbed/28749/what-is-keynote-240-outcome-in-hcc?channelName=obr&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit=" frameborder="0" allowfullscreen="allowfullscreen" allow="autoplay" scrolling="no">iFrame is not supported!</iframe></div>

Embed (Object):

<div class="embed-responsive embed-responsive-16by9"><object width="640" height="360"><param name="movie" value="https://oncologytube.com/videoEmbed/28749/what-is-keynote-240-outcome-in-hcc?channelName=obr&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit="></param><param name="allowFullScreen" value="true"></param><param name="allowscriptaccess" value="always"></param><embed src="https://oncologytube.com/videoEmbed/28749/what-is-keynote-240-outcome-in-hcc?channelName=obr&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit=" allowscriptaccess="always" allowfullscreen="true" width="640" height="360"></embed></object></div>

Link (HTML):

<a href="https://oncologytube.com/v/28749?channelName=obr"><img src="https://oncologytubecom.cdn.ypt.me/videos/video_190628183617_0861/video_190628183617_0861.jpg?cache=15669161101678829655">What is KEYNOTE 240 Outcome in HCC</a>

Link (BBCode):

[url=https://oncologytube.com/v/28749?channelName=obr][img]https://oncologytubecom.cdn.ypt.me/videos/video_190628183617_0861/video_190628183617_0861.jpg?cache=15669161101678829655[/img]What is KEYNOTE 240 Outcome in HCC[/url]

Sign in now!

Permanent Link

URL Friendly (SEO)

Current Time (SEO)

Category:

Other

Description:

Daneng Li, MD, Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research, Liver Program Disease Team Lead, City of Hope, explains the outcomes from KEYNOTe 240 trial comparing pembrolizumab versus placebo in 1st line hepatocellular carcinoma (HCC) patients.